Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesSingle-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor-alpha; therapy: Is there a need for more comprehensive screening procedures?
Arthritis Care and Research , 06/03/09
Nannini C et al. – The results of randomized controlled trials (RCTs) show that 26% of malignancies occur within 12 weeks from enrollment in patients receiving anti-TNF therapies suggesting the need for a revision of current cancer screening procedures in RCTs and in clinical practice.
Methods- A systematic review to monitor the occurrence of malignancies among pts with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) treated with anti-TNF therapy
- Primary outcome: report of frequency of malignancies in RCTs and the latency between the therapy introduction and the occurrence of the neoplasm
- 363 consecutive RA, PsA, and AS pts requiring anti-TNF therapy from 2002 to 2006, underwent extensive cancer screening procedures
- An historical controlled group of 73 pts treated between Jan 1999 and Dec 2001 underwent the screening procedures accepted for the RCT procedures
- 36 RCTs; malignancies occurred in 60/8,015 (0.75%) pts randomized to the active treatment arm and in 21/3,991 (0.52%) pts in the placebo arms
- In the personal retrospective case series, 0.27% pts and 4.1% controls developed cancer over the f/u period
- Mean ± SD f/u duration was 40.9 ± 16.7 mo in study pts and 50.6 ± 18.1 mo in controls
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Breast cancer in the elderly: a histological assessment
Histopathology, 10/15/09
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Sponsor
Article Search
Sponsor
Sponsor